Colorectal Cancer Screening Simplified.

Transforming Colorectal Cancer Screening Through Molecular Precision and Patient Adherence.

The Challenge: The "Unscreened" 1 in 3

Despite the clinical gold standard of colonoscopy, nearly 33% of eligible adults remain non-compliant due to the invasive nature of traditional screening or the "aversion factor" of stool-based kits. ColoHealth™ bridges the gap, offering a high-compliance, blood-based alternative for average-risk patients who have previously declined other methods.

Clinical Performance & Utility

Move the conversation from "convenience" to "diagnostic confidence."

  • 99.7% Negative Predictive Value (NPV): Validated by robust clinical data, providing high confidence in negative results for average-risk populations.
  • Validated Biomarker: Utilizes Real-Time PCR to detect methylated Septin 9 (mSEPT9) DNA, a proven molecular marker for colorectal neoplasia.
  • CLIA & ISO 13485 Certified: All testing is performed in our vertically integrated, high-complexity central laboratory.
  • Actionable Results: A positive result serves as a powerful motivator for diagnostic colonoscopy, with studies showing significantly higher follow-up rates compared to stool-test refusals.
Doctor Using the ColoHealth Ordering Portal

Work Your Way

Seamless Practice Integration

We’ve designed the NewDay Physician Portal to be an extension of your practice’s workflow. Whether you prefer digital-first ordering or traditional manual processing, our system adapts to you.

 

  • Dedicated Physician Portal: Centralized dashboard to place orders, manage patient kits, and track real-time test progress from "Sample Received" to "Processing."
  • Flexible Ordering: Order directly through the secure portal or utilize our manual requisition process to suit your specific business operations.
  • Invoicing & Bulk Logistics: No per-kit transactions. We provide consolidated monthly invoicing, allowing your staff to focus on patient care rather than payment processing.
  • Secure Result Delivery: To maintain the highest standards of HIPAA compliance and data integrity, results are delivered securely via encrypted email, ensuring they reach the clinician's desk immediately upon validation.

How It Works: The Clinician Workflow

Identify & Order

Identify non-adherent, average-risk patients. Place the order via the Portal or manual form.

Collection

The patient visits a local phlebotomy site or has blood drawn in-office. No bowel prep or dietary restrictions required.

Monitor

Track the sample status through the Physician Portal. Call or email us for status updates if you've opted out of portal access.

Review

Receive the finalized, secure Clinical Lab Report via encrypted email within 7–10 business days.

Find the Answers You Need

Whether you have a question about our testing solutions or need assistance with our services, we’re here to help. Share a few details below, and a member of the New Day team will reach out to you shortly.

What Can I Do Next?

Contact us to find out how to join the program.  If your already are a ColoHealth Participating Physican, use the button below to access the portal.

INDICATIONS FOR USE

ColoHealth Direct is a Laboratory Developed Test for the detection of methylated Septin 9. Methylated Septin 9 is a qualified predictor of early onset colorectal cancer.

ColoHealth Direct is intended for use in those who are age 50 or older, with no history of colon cancer, gastrointestinal abnormalities (such as IBS, Crohn’s disease, diverticulosis, etc), or symptoms of colon cancer (such as changes in bowel habits or blood in stool), no history of colon cancer in first degree relatives (mother, father, sibling), and no history of any hereditary cancer syndromes (such as Lynch syndrome).

Research has shown that testing for methylated Septin 9 may be beneficial for other populations such as those who are under age 50, those who may be symptomatic, those who have had a family history of cancer, or those who may have a history of hereditary cancer syndromes. Test performance in individuals under 50 is limited to retrospective case-control data in a study of 27 early onset colorectal cancer cases with a median age of 44.

 

WARNINGS, LIMITATIONS, & PRECAUTIONS

The ColoHealth Direct™ test is not intended to replace colorectal cancer screening tests that are recommended by appropriate guidelines (e.g., 2021 USPSTF guidelines) such as colonoscopy, sigmoidoscopy, and high sensitivity fecal occult blood testing. The ColoHealth Direct test is not intended for patients who are willing and able to undergo routine colorectal cancer screening tests that are recommended by appropriate guidelines.

There is limited research data currently available demonstrating that ColoHealth Direct could be indicated for those under age 50 and/or those with the following conditions:  those with an elevated risk of developing CRC based on previous history of colorectal polyps, CRC or related cancers, inflammatory bowel disease (IBD), chronic ulcerative colitis, Crohn’s disease, familial adenomatous polyposis, family history of CRC, hereditary cancer syndrome (HNPCC or Lynch Syndrome), Peutz-Jeghers syndrome, MAP, Gardner’s syndrome, Turcot’s (Crail’s) syndrome, Cowden’s syndrome, Cronkhite-Canada syndrome, Neurofibromatosis, Familial Hyperplastic Polyposis, or in those with anorectal bleeding hematochezia, or with known iron deficiency anemia.

REFERENCES

Loomans-Kropp HA, Song Y, Gala M, Parikh AR, Van Seventer EE, Alvarez R, Hitchins MP, Shoemaker RH, Umar A. Methylated Septin9 (mSEPT9): A promising blood-based biomarker for the detection and screening of early-onset colorectal cancer. Cancer Res Commun. 2022 Feb;2(2):90-98. doi: 10.1158/2767-9764.crc-21-0142. Epub 2022 Feb 11. PMID: 35992328; PMCID: PMC9387652.

 Song, L., Jia, J., Peng, X. et al. The performance of the SEPT9 gene methylation assay and a comparison with other CRC screening tests: A meta-analysis. Sci Rep 7, 3032 (2017). https://doi.org/10.1038/s41598-017-03321-8

 Hitchins MP, Vogelaar IP, Brennan K, Haraldsdottir S, Zhou N, Martin B, Alvarez R, Yuan X, Kim S, Guindi M, Hendifar AE, Kalady MF, DeVecchio J, Church JM, de la Chapelle A, Hampel H, Pearlman R, Christensen M, Snyder C, Lanspa SJ, Haile RW, Lynch HT. Methylated SEPTIN9 plasma test for colorectal cancer detection may be applicable to Lynch syndrome. BMJ Open Gastroenterol. 2019 May 28;6(1):e000299. doi: 10.1136/bmjgast-2019-000299. PMID: 31275589; PMCID: PMC6577308.